340B Drug Pricing Program
The rapidly rising costs of prescription drugs is causing significant financial challenges for patients and their care providers.
Many groups, including the AHA, are evaluating options for addressing this important issue. However, one recent proposal, which is seriously misguided, would reduce a…
AHA Digital Advocacy Resources for 340B Program
The AHA last week criticized as “misdirected” and a blow to patient care the Medicare Payment Assessment Commission’s (MedPAC) recommendation that Congress reduce Part B drug payment rates to hospitals participating in the 340B Drug Pricing Program.
At its Jan. 14 meeting, the commission voted 14…
The AHA today urged the Medicare Payment Advisory Commission to withdraw its draft recommendation to reduce Part B drug payment rates to hospitals participating in the 340B Drug Pricing Program. “This recommendation is outside of the scope of MedPAC’s mission, lacks a clear purpose and penalizes…
More than 20 years ago, Congress created the 340B Drug Pricing Program to allow eligible hospitals and health systems to stretch limited resources and expand access to care for vulnerable patients. But despite a proven track record of increasing patient access to vital medical services and…
This infographic PDF urges Congress to preserve the 340B program to protect access to care.
The Health Resources and Services Administration (HRSA) released today its long-awaited proposed 340B Drug Pricing Program "Mega Guidance" in the form of a notice with a 60-day comment period.